Data Insights

Durvalumab by AstraZeneca for Vulvar Cancer: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Vulvar Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Vulvar Cancer

Data Insights

Durvalumab by AstraZeneca for Vaginal Cancer: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Vaginal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Vaginal Cancer

Data Insights

Durvalumab by AstraZeneca for Anal Cancer: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Anal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Anal Cancer

Data Insights

Durvalumab by AstraZeneca for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Durvalumab by AstraZeneca for Dedifferentiated Liposarcoma: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Dedifferentiated Liposarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Dedifferentiated Liposarcoma

Data Insights

Durvalumab by AstraZeneca for Leiomyosarcoma: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Leiomyosarcoma

Data Insights

Durvalumab by AstraZeneca for Melanoma: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Melanoma

Data Insights

Durvalumab by AstraZeneca for Angiosarcoma: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Angiosarcoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Angiosarcoma

Data Insights

Durvalumab by AstraZeneca for Metastatic Melanoma: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Metastatic Melanoma

Data Insights

Durvalumab by AstraZeneca for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase III for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Durvalumab by AstraZeneca for Gastric Cancer: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase III for Gastric Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Gastric Cancer

Data Insights

Durvalumab by AstraZeneca for Peritoneal Cancer: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase III for Peritoneal Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Peritoneal Cancer

Data Insights

Durvalumab by AstraZeneca for Fallopian Tube Cancer: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase III for Fallopian Tube Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Fallopian Tube Cancer

Data Insights

Durvalumab by AstraZeneca for Pancreatic Cancer: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Pancreatic Cancer

Data Insights

Durvalumab by AstraZeneca for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Metastatic Adenocarcinoma of The Pancreas

Data Insights

Durvalumab by AstraZeneca for Extrahepatic Bile Duct Cancer: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase III for Extrahepatic Bile Duct Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Extrahepatic Bile Duct Cancer

Data Insights

Durvalumab by AstraZeneca for Soft Tissue Sarcoma: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Soft Tissue Sarcoma

Data Insights

Durvalumab by AstraZeneca for Epithelial Ovarian Cancer: Likelihood of Approval

Durvalumab is under clinical development by AstraZeneca and currently in Phase III for Epithelial Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Epithelial Ovarian Cancer